Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings

Group 1 - MacroGenics reported $110.71 million in revenue for Q3 2024, a year-over-year increase of 964.5% [1] - The EPS for the same period was $0.90, compared to -$0.52 a year ago, representing a significant turnaround [1] - The reported revenue exceeded the Zacks Consensus Estimate of $97.04 million by 14.09% [1] Group 2 - Product sales, net, were $4.16 million, below the four-analyst average estimate of $6.05 million, reflecting an 11.4% decrease year-over-year [3] - Revenue from collaborative and other agreements was $101.41 million, significantly surpassing the estimated $72.94 million, marking a year-over-year increase of 11358.5% [3] - Revenue from government agreements was $0.57 million, slightly above the estimated $0.45 million, with a year-over-year increase of 64.1% [3] Group 3 - MacroGenics shares have returned +3.1% over the past month, outperforming the Zacks S&P 500 composite, which declined by -0.5% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [4]